People
Talaris, most recently known as Regenerex, will use the funding to launch a Phase III registration trial of its allogenic cell therapy in living donor kidney transplant recipients.
Research Fellow from German Research Center for Artificial Intelligence to lead team driving solutions for pharmaceutical partners
As Ned Sharpless takes over as acting commissioner of the U.S. Food and Drug Administration, he is not planning any disruptions or course corrections to the federal regulatory agency.
Janssen Pharmaceuticals presented data that showed its RNAi therapeutic candidate exhibited robust effects on the liver disease that takes the lives of more than 900,000 people annually.
The life science industry is continually making advancements in every area! We want to know what cool science innovations are currently in progress and the professionals behind them.
Stephen Quake, a Stanford University bioengineer and inventor, recently shared several years’ worth of email communications between himself and He with The New York Times.
Although it was probably not in serious jeopardy, Bristol-Myers Squibb’s shareholders voted today to approve the acquisition of Celgene Corporation for about $74 billion.
The biopharma and medtech ecosystem in New Hampshire is growing thanks, in part, to state-supported tax exemptions and an increasing number of regenerative medicine manufacturing companies setting up shop in the Granite State.
Biopharma companies tap new hires to assume roles in leadership positions, with additions at Metrion, JDRF, Ribometrix, and more.
There is a war going on in the health care industry and the enemy is winning. That enemy is bacteria, fungi and other pathogens that have become resistant to treatment with conventional medicines.
PRESS RELEASES